Biohaven Pharma Alzheimers treatment Troriluzole to continue late-stage study

Biohaven Pharmaceutical's study of its experimental Alzheimer's treatment, Troriluzole is being led by the Alzheimer's Disease Cooperative Study (ADCS) at the University of California San Diego School of Medicine.

New Delhi: Biohaven Pharmaceutical said recently that it would continue with a late-stage study of its experimental Alzheimer's treatment on the recommendation of an independent data-monitoring committee based on an interim analysis of results.

In order to pass the analysis, the treatment Troriluzole had to demonstrate numerically greater benefit over placebo on at least one of two pre-specified criteria: a measure of cognitive function or hippocampal volume assessed by magnetic resonance imaging.

The study is being led by the Alzheimer's Disease Cooperative Study (ADCS) at the University of California San Diego School of Medicine.

Read Also: Suven Life Sciences Alzheimers drug Masupirdine fails to meet the primary endpoint

Alzheimer's is a progressive neurodegenerative disorder that causes brain cells to waste away and die and accounts for 60%-80% of dementia cases.

Read Also: Biogen Alzheimer drug Aducanumab failure wipes USD 18 billion from market value